Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDevonian Health Group Inc

Devonian Health Group Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.74 CAD 0.00(0%)
Last update at 2026-11-02T14:30:00Z
Market Cap
27.84M

Momentum Score

…

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.74
Low
7.74
High
52 Week Price Range
0.19
Low
15.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Devonian Health Group Inc (GSD.V) is a small-cap, publicly listed life sciences and health products company on the TSX Venture Exchange; public disclosures about its operations and pipeline are limited. Its longer-term growth drivers appear to be product development and commercialization in the health and wellness sector, potential regulatory progress and strategic partnerships, which may benefit investors seeking early-stage exposure to health-product development.
Principal risks include limited operating and disclosure history, execution and regulatory uncertainty, dependence on additional financing and low market liquidity that could amplify share volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.74
Dividend Yield
-
Revenue TTM
10.18M
Revenue Per Share
3.89
Gross Profit TTM
4.53M
Debt / Equity
-
ROE
-83.36%
Net Debt
1.45M
ROCE
-8.37%
Diluted EPS TTM
-3.47

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -5.59M -0.98M -4.60M -3.45M -3.35M
Net income -6.01M -1.83M -4.60M -3.45M -3.35M
Selling general administrative 7.32M 6.81M 3.86M 2.70M 1.45M
Gross profit 8.56M 7.48M 0.89M 0.56M -0.24M
Reconciled depreciation 0.35M 0.67M 0.42M 0.86M 1.03M
Ebit - - - -2.91M -2.31M
Ebitda - - - -1.65M -1.52M
Operating income -0.77M -0.61M -4.32M -2.91M -2.26M
Interest expense 0.14M 0.37M 0.46M 0.94M 0.79M
Tax provision 0.42M 0.85M - - -
Interest income 0.28M 0.07M 0.18M 0.04M -
Net interest income 0.02M -0.37M -0.28M -0.90M -0.79M
Total revenue 23.59M 19.31M 2.35M 2.31M 1.47M
Total operating expenses 24.36M 19.92M 6.67M 5.22M 3.73M
Cost of revenue 15.03M 11.83M 1.45M 1.74M 1.72M
Total other income expense net -4.84M - - 0.36M -0.29M
Net income from continuing ops -6.01M -1.83M -4.60M -3.45M -3.35M
Net income applicable to common shares - - - -3.45M -3.35M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 15.83M 30.73M 19.18M 21.59M 14.61M
Intangible assets 4.90M 5.13M 5.51M 5.64M 6.23M
Total liab 6.69M 16.27M 4.93M 5.31M 7.08M
Total stockholder equity 9.14M 14.46M 14.25M 16.27M 7.52M
Common stock - - - 27.57M 20.21M
Capital stock 29.84M 29.84M 29.35M 27.57M 20.21M
Retained earnings -33.27M -26.65M -25.43M -20.83M -17.38M
Good will 0.00M 4.64M 4.64M 4.64M 4.64M
Cash 6.98M 9.86M 5.06M 2.81M 0.34M
Total current liabilities 6.61M 16.15M 4.86M 1.04M 1.81M
Net debt - - - 1.45M 4.91M
Short long term debt - 2.08M 3.58M - -
Other stockholder equity - - - 5.85M 1.31M
Property plant equipment - - - 2.88M 3.07M
Total current assets 8.72M 18.46M 6.34M 8.42M 0.66M
Net tangible assets - - - 5.99M -3.35M
Short term investments - - 0.00M 5.00M -
Net receivables 0.48M 7.69M 0.66M 0.34M 0.24M
Long term debt - - - 4.26M 5.26M
Inventory 0.03M 0.06M 0.16M 0.15M 0.03M
Accounts payable 4.36M 3.72M 0.75M 0.41M 0.56M
Non current assets total 7.11M 12.27M 12.83M 13.17M 13.94M
Capital lease obligations 0.13M 0.17M 0.09M 0.02M 0.02M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - 0.00M 5.00M -5.00M -5.00M
Change to liabilities - - - -0.31M -0.89M
Total cashflows from investing activities - - - -5.08M -0.01M
Net borrowings -2.21M -1.55M - -0.53M 0.05M
Total cash from financing activities -1.61M -0.84M 1.61M 10.41M 1.28M
Change to operating activities - - - -0.07M 0.15M
Net income -6.01M -1.83M -4.60M -3.45M -3.35M
Change in cash -2.88M 4.80M 2.26M 2.46M -0.57M
Begin period cash flow 9.86M 5.06M 2.81M 0.34M 0.91M
End period cash flow 6.98M 9.86M 5.06M 2.81M 0.34M
Total cash from operating activities -1.25M 5.64M -4.36M -2.87M -1.83M
Issuance of capital stock 0.60M 0.71M 1.16M 10.76M 1.18M
Depreciation 0.35M 0.67M 0.42M 0.85M 1.02M
Other cashflows from investing activities - - - -0.01M -0.01M
Change to inventory 0.03M 0.10M -0.01M -0.13M 0.06M
Change to account receivables 6.83M -7.10M -0.55M -0.10M 0.29M
Change to netincome - - - 0.31M 0.87M
Capital expenditures 0.02M 0.00M 0.00M 0.07M 0.07M
Change in working capital -1.63M 5.21M -0.32M -0.60M -0.39M
Stock based compensation 0.69M 0.73M 0.48M 0.53M 0.08M
Other non cash items 0.09M 0.01M -0.35M 0.14M 0.49M
Free cash flow -1.27M 5.64M -4.36M -2.95M -1.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GSD
Devonian Health Group Inc		 -
-%		 7.74 - - 2.73 3.52 2.62 -16.66
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
1.96%		 0.50 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 0.01
10.00%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 0.01
1.61%		 0.63 - - - 15.17 - -58.16

Profile*

Devonian Health Group Inc

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.

360, rue des Entrepreneurs, Québec, QC, Canada, G5V 4T1

450 979 2916

https://groupedevonian.com

8

Name Title Year Born
Ms. Colette Laurin C.A., CPA Interim CFO, Corp. Sec. & Corp. Controller NA
Dr. Andre P. Boulet Ph.D. Chief Scientific Officer 1959
Mr. Pierre J. Montanaro Pres, CEO & Director NA
Mr. Martin Moreau C.F.A., M.Sc. VP of Fin. & Director NA
Dr. Andre P. Boulet Ph.D. Chair of the Board, COO & Chief Scientific Officer 1959
Mr. Luc D. Gregoire CA, CPA President, CEO & Director 1960
Ms. Colette Laurin C.A., CPA Interim CFO, Corporate Secretary & Corporate Controller NA
Dr. Andre P. Boulet Ph.D. COO, CEO, Chief Scientific Officer & Chair of the Board 1959
Mr. Luc D. Gregoire CA, CPA Executive VP of Strategy & Director 1960
Ms. Viktoria Krasteva Chief Financial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…